An eleven-year experience with adrenocortical carcinoma

Area of Science:

• Oncology
• Surgical Oncology
• Adrenal Gland Cancer Research

Background:

• Adrenocortical carcinoma treatment faces challenges including adjuvant therapy efficacy, reoperation benefits, and chemotherapy options.
• Evaluating these critical issues is essential for improving patient outcomes.

Purpose of the Study:

• To assess the impact of adjuvant therapy, reoperation, and chemotherapy on adrenocortical carcinoma treatment outcomes.
• To identify prognostic factors and guide surgical and medical management strategies.

Main Methods:

• Retrospective analysis of 73 patients with adrenocortical carcinoma.
• Evaluation of treatment strategies including surgery, adjuvant therapy (mitotane, radiation), and chemotherapy for recurrent disease.

Main Results:

• Complete resection offered a 47% 5-year survival rate, compared to 35% overall.
• Adjuvant therapy did not improve disease-free intervals; 85% of patients experienced recurrence.
• Reoperation for recurrent disease significantly improved survival (56 months vs. 19 months with medical treatment).
• Mitotane showed a 24% partial response rate; other chemotherapies were ineffective.

Conclusions:

• An aggressive surgical approach for recurrent and metastatic adrenocortical carcinoma is recommended.
• Complete resection should be prioritized whenever feasible.
• Currently, no effective chemotherapy exists, and the value of adjuvant therapy remains unproven.